Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.56 |
| ▸ | TUBB | P07437 | 1/20 | 0.56 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.56 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.56 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.56 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.56 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.56 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.56 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.56 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.56 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.56 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.56 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.56 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.56 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.56 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541953 | 0.85 | POLB (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30640906 | 0.85 | POLB (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL28302287 | 0.85 | PDCD1 (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3665663 | 0.84 | TUBB4A (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3544818 | 0.84 | NNMT (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3878179 | 0.83 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13473869 | 0.83 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL28795121 | 0.83 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27686214 | 0.83 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9264129 | 0.82 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634424-B2 | Diazaindole derivative and use thereof as CHK1 inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2023-04-25 | — | — | US | disclosed |
| US-20230017858-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (CN) | 2023-01-19 | — | — | US | disclosed |
| WO-2021104461-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | 南京明德新药研发有限公司 | 2021-06-03 | — | — | WO | disclosed |
| US-7572808-B2 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572808-B2 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572808-B2 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1891068-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| WO-2006138734-A1 | TRIAZOLOPYRIMIDINE CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138695-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017858-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | CHEK1, CHEK2, DDB1 | TUBB4A 2386/4885TUBB 1732/4885TUBA3C 2808/4885 |
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | CNR1, CNR2, GPR68 | TUBB4A 3464/4885TUBB 3170/4885TUBA3C 2991/4885 |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | CNR1, CNR2, TRPV1 | TUBB4A 3251/4885TUBB 2583/4885TUBA3C 2177/4885 |
| US-11634424-B2 | Diazaindole derivative and use thereof as CHK1 inhibitor | CHEK1, CHEK2, DDB1 | TUBB4A 2386/4885TUBB 1732/4885TUBA3C 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.